Spark Biomedical concluded enrollment for its pivotal clinical trial using transcutaneous auricular neurostimulation (tAN) to improve treatment retention for adults with opioid use disorder. The National Institute on Drug Abuse (NIDA) funded the study, conducted in partnership with the Hazelden Betty Ford Foundation and Gaudenzia, examining tAN’s effectiveness alone and with existing medications for opioid use disorder. The trial aims to provide a non-invasive, drug-free method for supporting long-term recovery.
This successful trial completion is a critical advancement in addressing the opioid crisis, particularly given the rise in fentanyl-related overdoses and high relapse rates. It offers a potential alternative or supplement to current pharmacotherapies, potentially expanding treatment options and improving patient engagement, which is crucial for successful recovery. The non-invasive nature of tAN could lower the barrier to entry for individuals hesitant about medication-assisted treatment.
The study investigated tAN’s potential synergistic effects with lofexidine and XR-naltrexone, two approved medications for opioid use disorder. The trial’s completion allows for data analysis and subsequent preparation for an FDA submission. The partnership with established institutions like Hazelden Betty Ford and Gaudenzia highlights the significance and collaborative nature of this research.
The trial’s results and potential FDA approval could significantly impact the landscape of opioid use disorder treatment. A non-invasive, drug-free option like tAN could increase access to care, potentially leading to improved patient outcomes and reduced relapse rates. This innovation may also spur further research and development in bioelectronic medicine for addiction and other behavioral health conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
